CYLD anticorps (C-Term)

N° du produit ABIN6261163

Détail du produit anti-CYLD anticorps

Antigène: CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))

Épitope: C-Term

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CYLD est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Specificité: CYLD Antibody detects endogenous levels of total CYLD.

Homologie: Pig,Bovine,Horse,Sheep,Rabbit,Dog,Chicken,Xenopus

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogène: A synthesized peptide derived from human CYLD, corresponding to a region within C-terminal amino acids.

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000, IHC 1:50-1:200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20 °C. Stable for 12 months from date of receipt.

Date de péremption: 12 months

Détails sur CYLD

Antigène: CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))

Autre désignation: CYLD (CYLD Produits)

Synonymes: anticorps BRSS, anticorps CDMT, anticorps CYLD1, anticorps CYLDI, anticorps EAC, anticorps MFT, anticorps MFT1, anticorps SBS, anticorps TEM, anticorps USPL2, anticorps 2010013M14Rik, anticorps 2900009M21Rik, anticorps C130039D01Rik, anticorps mKIAA0849, anticorps cyld, anticorps LRRGT00003, anticorps Rp1, anticorps Rp1h, anticorps CYLD lysine 63 deubiquitinase, anticorps cylindromatosis (turban tumor syndrome), a, anticorps CYLD, anticorps Cyld, anticorps cylda

Sujet:

Description: Deubiquitinase that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation (PubMed:12917689, PubMed:12917691). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane, this process does not depend on NF-kappa-B activation (By similarity). Also able to remove linear ('Met-1'-linked) polyubiquitin chains to regulate innate immunity: recruited to the LUBAC complex and, together with OTULIN, restricts linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed:26670046, PubMed:26997266).

Gene: CYLD

Poids moléculaire: 110 kDa

ID gène: 1540

UniProt: Q9NQC7

Pathways: Apoptose, Activation of Innate immune Response